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Abstract
Phase I dose-finding trials are increasingly chal-
lenging as the relationship between efficacy and
toxicity of new compounds (or combination of
them) becomes more complex. Despite this,
most commonly used methods in practice fo-
cus on identifying a Maximum Tolerated Dose
(MTD) by learning only from toxicity events. We
present a novel adaptive clinical trial methodol-
ogy, called Safe Efficacy Exploration Dose Al-
location (SEEDA), that aims at maximizing the
cumulative efficacies while satisfying the toxicity
safety constraint with high probability. We evalu-
ate performance objectives that have operational
meanings in practical clinical trials, including
cumulative efficacy, recommendation/allocation
success probabilities, toxicity violation probabil-
ity, and sample efficiency. An extended SEEDA-
Plateau algorithm that is tailored for the increase-
then-plateau efficacy behavior of molecularly tar-
geted agents (MTA) is also presented. Through
numerical experiments using both synthetic and
real-world datasets, we show that SEEDA out-
performs state-of-the-art clinical trial designs by
finding the optimal dose with higher success rate
and fewer patients.
1. Introduction
An adaptive clinical trial utilizes the accumulated results to
dynamically modify its future trajectory for better efficiency
and ethics, while preserving the integrity and validity of the
study. Studies such as the phase I trial in Acute Myeloid
Leukaemia in (Yap et al., 2013) and Cancer Research UK
study CR0720-11 in (Whitehead et al., 2012) have suggested
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that even some simple forms of adaptive design lead to better
usage of resources and require fewer participants. These
promising results have spawned the interest in developing
adaptive clinical trial methodologies in recent years (Villar
et al., 2015a; Pallmann et al., 2018; Atan et al., 2019; Lee
et al., 2020), which is of great importance because running
an actual clinical trial on human subjects is expensive and
ethically sensitive. A well-designed trial methodology with
thorough theoretical and simulated investigation is widely
acknowledged as a crucial first step.
Traditionally, the goal of phase I clinical trials is to iden-
tify the Maximum Tolerated Dose (MTD) of a cytotoxic
(CTX) or therapeutic agent, which is then used for subse-
quent studies (Storer, 1989). However, modern cancer phase
I trials test antineoplastic agents in patients with advanced
cancer stages, who have often exhausted all other available
treatment options (Roberts et al., 2004). These participants
usually expect therapeutic benefit from participating in the
trial, which has motivated the trial design to include ef-
ficacy as a co-primary end point of phase I dose-finding
studies (Yan et al., 2017; Paoletti & Postel-Vinay, 2018). In
addition, the monotonic assumption for the dose-efficacy
relationship is widely adopted in state of the art designs,
which is reasonable for cytotoxic agents but may not ap-
ply to the new molecularly targeted agents (MTA) such as
monoclonal antibodies (see (Postel-Vinay et al., 2009) for
an exemplary trial that illustrates this issue). Designing
adaptive clinical trials that can properly address the intrinsic
conflict between learning and treatment effectiveness for
general dose-response models has become an important task
for phase I clinical trials.
In addition to the well-known 3+3 design (Storer, 1989) and
continual reassessment method (CRM) (O’Quigley et al.,
1990) (and its many variants), Bayesian approaches such
as Thompson Sampling (TS) (Aziz et al., 2019) and Gittins
index (Villar et al., 2015a;b) have been proposed in the liter-
ature for dose-finding studies. However, these methods were
originally designed for simplified models that do not capture
some of the unique characteristics of clinical trials, often
leading to lack of randomization (Villar et al., 2015b), ineffi-
cient use of side information (Villar & Rosenberger, 2018),
and reduced power levels and estimation issues. Notably,
for cases where the best dose for combination therapies
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Table 1: Representative adaptive clinical trial studies
Study Treatment Category Methodology Evaluation
(Tighiouart et al., 2014) Veliparib CTX EWOC-PH simulated trial
(Whitehead et al., 2012) MK-0752 CTX joint phase I and II design simulated trial
(Lee et al., 2017) Erlotinib MTA extended TITE-CRM simulated trial
(Thiessen et al., 2010) Lapatinib MTA escalation to DLT real-world trial data
is to be found, unknown synergistic/antagonist effects are
likely to exist and naive designs will fail to identify them.
For MTA, the existence of a plateau of efficacy has been
discussed in (Zang et al., 2014) and (Riviere et al., 2018),
which indicates that the toxicity constraint must be jointly
studied with the dose-efficacy relationship for certain new
compounds. This is also confirmed by the real-world trial
result; see (Tighiouart et al., 2014). Last but not the least,
safety constraints such as minimizing the adverse events
(AE) (Petroni et al., 2017) have not been properly evalu-
ated with theoretical guarantees. Table 1 summarizes some
representative studies in this direction.
In this paper, we address these challenges by developing
new dose-finding methods that explicitly impose safety con-
straints to the allocation and recommendation of dose levels
in a phase I clinical trial. We propose the Safe Efficacy
Exploration Dose Allocation (SEEDA) algorithm that adap-
tively updates the admissible set of dose levels satisfying
the safety constraints, thus limiting the exploration of doses
with harmful effect. Performance analysis for SEEDA is
carried out with respect to several measures that have opera-
tional meanings in clinical trials, including the probability
of safety constraints violation, the average efficacy for pa-
tients, and the recommendation and allocation probabilities.
Noting that SEEDA only leverages the dose-toxicity logis-
tic model and makes no assumptions on the efficacy, we
then show that, by considering the increasing-then-plateau
feature of the dose-efficacy relationship for MTA, SEEDA-
Plateau leads to better performance by leveraging the uni-
modal structure. Experiments on simulated datasets as well
as clinical trials built from real-world datasets show that the
proposed methods are capable of finding the optimal dose
with higher success rate and fewer patients in most cases,
compared to other state-of-the-art designs.
2. Model and problem formulation
2.1. The dose-finding model
In a phase I dose-finding clinical trial, a total of K doses are
given where the k-th dose is denoted as dk ∈ D, k ∈ K =
{1, 2, ...,K}. The performance is characterized by both
efficacy and toxicity. We model the efficacy X and toxicity
Y for dose dk as Bernoulli random variables with unknown
probabilities qk and pk, respectively, where X = 1 (X = 0)
indicates that the dose level is effective (not effective), and
Y = 1 (Y = 0) suggests that the dose is harmful (not
harmful) to the patient1.
We consider adaptive clinical trials where information
learned from previous trial patients can be used in allocating
doses to subsequent patients (Atan et al., 2019; Villar et al.,
2015a; Aziz et al., 2019). For the t-th patient, dose I(t) is
selected based on a policy that uses past observations, and
administrated to the patient. The efficacy outcome Xt and
toxicity response Yt are realized based on their distributions
Xt ∼ Ber(qI(t)) and Yt ∼ Ber(pI(t)), and observed by
the trialist.
We adopt a well-known dose-toxicity logistic model pro-
posed by in (O’Quigley et al., 1990) to describe the toxicity
probability for different dose levels:
pk(a) =
(
tanh dk + 1
2
)a
, (1)
where a is a global parameter for all the dose levels. It can
be verified that Eqn. (1) satisfies the assumption that the
toxicity monotonically increases with dose dk. The unsafe
dose levels are defined as those whose toxicity probabilities
pk’s are above a pre-determined target toxicity probability θ,
which is referred as the MTD threshold. Hence the toxicities
of all doses can be written as p1 ≤ p2 ≤ · · · ≤ pM <
θ < pM+1 ≤ · · · pK where the (unknown) M denotes the
number of safe doses. The efficacy-dose relationship is not
modeled to allow for the development of a general algorithm.
The specific increase-then-plateau efficacy behavior of MTA
will be exploited in Section 4.
2.2. Problem formulation
Several objectives are often desired for a successful dose-
finding study, which are summarized as follows.
• Successful recommendation. At the end of the trial (n
patients) a dose recommendation kˆn is made, which is
desired to match the optimal dose k∗ that is the lowest
safe dose that achieves the highest efficacy (Zang et al.,
2014): k∗ = min{k : pk ≤ θ, qk = maxl∈K ql}.
• Effective treatment. The cumulative treatment for trial
participants
∑n
i=1Xt is desired to be maximized.
1This is typically measured by the presence of absence of a
dose-limiting toxicity (DLT) reported in a fixed evaluation window
after administrating the drug.
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• Minimal violation of the safety constraint. There are
different formulations for the safety constraint. One is
to minimize E[
∑K
k=k∗+1Nk(n)/n] where Nk(t) denotes
the number of times dose k is allocated to the first t pa-
tients. Another formulation is to minimize the probability
that the average toxicity exceeds the MTD threshold.
• Small sample size. Most phase I trials have a pre-
determined nwhich is decided as the minimum number of
trial participants to achieve a pre-defined confidence level
of successful recommendation. It is desirable to have a
small n for cost and efficiency considerations.
Proposing a learning model that explicitly guarantees all
of the above objectives is elusive and non-constructive in
developing the dose-allocation policy. We thus formulate
dose-finding clinical trials as an online efficacy learning
problem with explicit safety constraint, and subsequently
provide performance analysis on the metrics of interest.
Specifically, we aim at maximizing the cumulative efficacy
over a finite number of patients n while simultaneously
guaranteeing that the average toxicity observed from the n
dose allocations is kept under the probability threshold θ
with high probability. This can be written as:
maximize E
[
n∑
t=1
Xt
]
subject to P
[
1
n
n∑
t=1
Yt ≤ θ
]
≥ 1− δ. (2)
Essentially, problem formulation (2) focuses on safe explo-
ration among all the dose levels to maximize cumulative
efficacies. Clinical trial designs for (2) thus need to pursue
both objectives of toxicity and efficacy.
3. The SEEDA algorithm
3.1. Algorithm description
The proposed Safe Efficacy Exploration Dose Allocation
(SEEDA) design is completely described in Algorithm 1. In
particular, pˆk(t) and qˆk(t) are the estimated toxicity and effi-
cacy, respectively, after administrating the t-th patient. The
principle of dose selection is to first dynamically construct
the admissible setD1(t) using the Upper Confidence Bound
(UCB) principle (Auer et al., 2002), where the confidence
interval α(t) is constructed as
α(t) = C¯1K
(
log 2Kδ
2t
) γ¯1
2
, (3)
where C¯1 and γ¯1 are algorithm parameters2. Note that the
admissible set consists of doses that, with high confidence,
satisfy the toxicity constraint.
2See Section B in the supplementary material for a discussion
on how to select these algorithm parameters.
Then, limiting to those in the admissible set D1(t), the algo-
rithm again applies the UCB principle (UCB-1 from (Auer
et al., 2002)) to select a dose with the largest F (p, s, n) for
the efficacy estimate:
F (p, s, n) = p+
√
c log(n)
s
, (4)
with c denoting the UCB-1 coefficient. It should be noted
that (4) can be replaced by other UCB principles, e.g., KL-
UCB (Garivier & Cappè, 2011).
Algorithm 1 The Safe Efficacy Exploration Dose Alloca-
tion (SEEDA) Algorithm
Input: pk(a) for each k ∈ K; MTD threshold θ; total
number of patients n.
Initialize: Nk(1) = 0, pˆk(1) = 0, qˆk(1) = 0, ∀k ∈ K;
Sample each dose once and set: I(t) = t, qˆI(t)(K) =
Xt, pˆI(t)(K) = Yt, NI(t)(K) = 1, for t = 1 to K;
t = K + 1.
1: while t ≤ n do
2: Compute the estimated parameter: aˆ(t) =∑K
k=1 wk(t− 1)aˆk(t− 1);
3: Set the admissible set: D1(t) = {dk ∈ D : pk(aˆ(t)+
α(t)) ≤ θ};
4: Select dose: I(t) =
arg maxdk∈D1(t) F (qˆk(t), Nk(t), t),;
5: Observe the revealed outcomes Xt and Yt;
6: Update estimations: qˆI(t)(t) =
qˆI(t)(t−1)NI(t)(t−1)+Xt
NI(t)(t−1)+1 , pˆI(t)(t) =
pˆI(t)(t−1)NI(t)(t−1)+Yt
NI(t)(t−1)+1 , NI(t)(t) = NI(t)(t−1)+1;
7: Update parameter estimation: aˆI(t)(t) =
arg min
a∈A
|pI(t)(a)− pˆI(t)(t)|;
8: Update weights: wk(t) = Nk(t)/t, ∀dk ∈ D;
9: t = t+ 1.
10: end while
Output: dˆ(n) = arg maxdk:pk(aˆ(n))≤θ pk(aˆ(n)).
3.2. Performance analysis
The SEEDA algorithm is developed with the aim to solve
problem (2). It is thus important to analyze (a) whether
the cumulative efficacy is maximized, and (b) how often
the toxicity constraint is violated. For metric (a), it can
be equivalently formulated as regret minimization, i.e., the
cumulative efficacy difference between the oracle policy
with full information and that of the learning algorithm.
Formally, the efficacy regret is defined as
R(n) = q∗n− E
[
n∑
t=1
qI(t)
]
, (5)
where q∗ = qk∗ denotes the efficacy associated with the
optimal dose defined in Section 2.2, and a∗ denotes the true
Learning for Dose Allocation in Adaptive Clinical Trials with Safety Constraints
parameter in (1). As for metric (b), we need to evaluate
e(n) = P
[
1
n
n∑
t=1
pI(t)(a
∗) > θ
]
,
in conjunction with (5), i.e., whether the proposed SEEDA
algorithm minimizes R(n) and satisfies e(n) ≤ δ at the
same time. In addition, other performance measures such
as successful recommendation probability and sample effi-
ciency are of practical interest, and we provide theoretical
guarantees for them as well. Due to space limitations, all
proofs are provided in the supplementary material.
3.2.1. CUMULATIVE EFFICACY
We start the theoretical analysis by showing that for each
patient t in SEEDA, the dose levels whose toxicities are
below the MTD threshold are included in the admissible set
with high probability. This corresponds to the type I error
event that is of interest in clinical trials.
Lemma 1 P [pk(aˆ(t) + α(t)) > θ] ≤ δ, ∀pk(a∗) ≤ θ.
Next we prove that with sufficient patients, the dose levels
exceeding the toxicity threshold are excluded from the ad-
missible set with high probability. This corresponds to the
type II error event in clinical trials.
Lemma 2 If t > t1 = 12
(
C¯1K
|∆−|
) 2
γ¯1
log 2Kδ , ∆ =
mink∈K∆k, then:
P [pk(aˆ(t) + α(t)) ≤ θ] ≤ exp(−2t2),∀pk(a∗) > θ.
(6)
Combining Lemmas 1 and 2 leads to the main result on
cumulative efficacy regret.
Theorem 1 With t1 defined in Lemma 2, the regret of
SEEDA can be upper bounded as:
R(n) ≤
∑
dk:pk(a∗)≤θ
c log(n)
q∗ − qk +
(
nδQ+
1
2
t1 +
K −M
22
)
(7)
where Q = maxi∈K |qi − qk∗ | denotes the maximal single-
step regret, and  > 0 is a constant.
Theorem 1 indicates that the efficacy regret is bounded by
O(log n). A closer look reveals that this scaling is caused
by the structureless model for efficacy – we impose no
assumption on the efficacy of different dose levels. The
structured model for toxicity, which affects the admissible
set, turns out to only cause a constant regret. As will be
shown in Section 4, with the increase-then-plateau efficacy
assumption, the log n regret scaling can be further improved.
3.2.2. SAFETY CONSTRAINT VIOLATION
We now move on to analyzing the safety constraint violation.
The first result is to verify whether the SEEDA algorithm
indeed satisfies the safety constraint in problem (2).
Theorem 2 For any given n, the average toxicity observed
from the SEEDA algorithm satisfies
P
[
1
n
n∑
t=1
pI(t) − θ ≤ C2γ2
]
≥ 1− δ,
for an arbitrary  > 0. C2 and γ2 are problem-dependent
parameters defined in Section A of the supplementary mate-
rial.
The safety constraint in problem (2) is formulated based
on the average toxicity exceeding the MTD threshold. In
practice, we are often interested in minimizing the number
of patients that have been exposed to unsafe dose levels,
E[
∑K
k=k∗+1Nk(n)/n]. Corollary 1 analyzes this metric.
Corollary 1 The number of unsafe dose allocations from
SEEDA, i.e., the selected dose levels exceed the MTD thresh-
old, can be bounded as:
E
 ∑
dk:pk>θ
Nk(n)
 ≤ t1 + K −M
22
.
Interestingly, Corollary 1 indicates that unsafe dose alloca-
tions in SEEDA are upper bounded by a constant, which is
linear in the number of unsafe doses K −M regardless of
the number of trial participants n.
3.2.3. RECOMMENDATION ACCURACY
Finally, we analyze the recommendation accuracy of
SEEDA at the end of the n-th dose allocation.
Corollary 2 The probability that SEEDA recommends the
optimal dose satisfies:
P
[
dˆ(n) = arg max
dk:pk≤θ
pk
]
≥ 1− δ1, (8)
where δ1 = 2K exp
(
−2
(
∆M
C1K
)2γ1
n
)
.
Corollary 2 guarantees the finding of the optimal dose level
with high probability. The recommendation error rate de-
cays exponentially with the number of trial participants,
which is a nice property. It is worth noting that a lower
bound of the minimal number of trial participants for a
given accuracy requirement can be inferred from the upper
bound of recommendation error rate (8). This is a practi-
cally important result, as sample efficiency directly relates
to the cost and ethical constraints of a trial. This is further
illustrated in the numerical experiments in Section 5.1.3.
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4. Extension to the increase-then-plateau
efficacy model
Algorithm 2 The SEEDA-Plateau Algorithm
Input: pk(a) for each k ∈ K; MTD threshold θ; total
number of patients n.
Initialize: Nk(1) = 0, pˆk(1) = 0, qˆk(1) = 0, ∀k ∈ K;
L(1) = K; η = 2; lk = 0, ∀k ∈ K; Sample each dose
once and set: I(t) = t, qˆI(t)(K) = Xt, pˆI(t)(K) = Yt,
NI(t)(K) = 1, for t = 1 to K; t = K + 1.
1: while t ≤ n do
2: Compute the estimated parameter: aˆ(t) =∑K
k=1 wk(t− 1)aˆk(t− 1);
3: Set the admissible set: D1(t) = {dk ∈ D : pk(aˆ(t)+
α(t)) ≤ θ};
4: Set L(t) = arg maxdk∈D1(t) qˆk(t) and increase lL(t)
by 1;
5: If lL(t)−1η+1 ∈ N, I(t) = L(t); Otherwise I(t) =
arg max
{L(t)−1,L(t),L(t)+1}⋂D1(t)
F (qˆk(t), Nk(t), t);
6: Observe the revealed outcomes Xt and Yt;
7: Update estimations: qˆI(t)(t) =
qˆI(t)(t−1)NI(t)(t−1)+Xt
NI(t)(t−1)+1 , pˆI(t)(t) =
pˆI(t)(t−1)NI(t)(t−1)+Yt
NI(t)(t−1)+1 , NI(t)(t) = NI(t)(t−1)+1;
8: Update parameter estimation: aˆI(t)(t) =
arg min |pI(t)(a)− pˆI(t)(t)|;
9: Update weights: wk(t) = Nk(t)/t, ∀dk ∈ D;
10: t = t+ 1.
11: end while
12: Estimate the turning point of efficacy as:
L1(n) = min
k:dk∈D1(n)
{
m ≥ k : |qˆm(n)− qˆm+1(n)|
≤
√
c log(n)
Nm(n)
+
√
c log(n)
Nm+1(n)
, qˆm(n) ≤ qˆm+1(n)
}
,
L2(n) = arg max
dk:pk(aˆ(n))≤θ
pk(aˆ(n)).
Output: dˆ(n) = min{L1(n), L2(n)}.
The proposed SEEDA dose allocation policy is general in
the sense that no efficacy model is assumed. In practice,
however, efficacy often exhibits certain structure which, if
utilized correctly, may further improve the performance.
For conventional cytotoxic agents, efficacy monotonically
increases with dose levels. The same is not true for MTAs,
for which the dose-efficacy curve increases initially and
then plateaus after reaching the level of saturation (Zang
et al., 2014; Riviere et al., 2018). In this section, we modify
the SEEDA algorithm to handle the increase-then-plateau
efficacy model, and analyze its performance.
Formally, we introduce the following increase-then-plateau
efficacy assumption, which holds for MTA.
Assumption 1 qk, k ∈ K satisfies q1 ≤ q2 ≤ q3 ≤ · · · ≤
qN = qN+1 = · · · = qK .
The SEEDA-Plateau algorithm is given in Algorithm 2.
With Assumption 1, the efficacy has an inherent non-
decreasing structure. The key idea is to combine the se-
lection rule of OSUB in (Combes & Proutière, 2014) and
reform step 4 in Algorithm 1. Note that step 4 calculates
L(t) as the estimated dose level with the optimal efficacy
and safe toxicity at t. Algorithm 2 not only selects this
dose level frequently enough, but also keeps exploring its
neighboring dose levels.
We now analyze the regret of SEEDA-Plateau and present
the result in Theorem 3. Compared to Theorem 1 for
SEEDA without the increase-then-plateau efficacy model,
one can see that the log(n) coefficient improves from
c
∑
dk:pk(a∗)≤θ(q
∗ − qk)−1 to c(q∗ − qN−1)−1. This gain
comes precisely from the increase-then-plateau efficacy
model, as the unimodal structure that exploits this struc-
ture leads to log(n) regret only from the neighboring arm.
Theorem 3 The regret of SEEDA-Plateau satisfies:
R2(n) ≤ c log(n)
q∗ − qN−1 +O (log log(n)) +
(
t1 +
K −M
22
)
.
(9)
Denoting the optimal dose level as φ∗ = min{M,N}, the
recommendation accuracy of SEEDA-Plateau is given in
Theorem 4.
Theorem 4 With c set as 2 < c < 52 , the probability that
SEEDA-Plateau fails to recommend the optimal dose can
be bounded as:
P[dˆ(n) 6= φ∗] ≤ 3
nc
+ δ1. (10)
Compared to Corollary 2, the error probability of SEEDA-
Plateau is increased by 3nc . This is due to the ambiguity
of the efficacy-optimal dose and the toxicity-optimal one,
which leads to the two candidate doses L1(n) and L2(n).
In practice, however, this ambiguity can be eliminated via
preliminary experiments.
5. Experiments
5.1. Synthetic dataset
To investigate the operational characteristics and evalu-
ate the performance of the proposed adaptive designs, we
present an experimental study with K = 6 dose levels and
n = 300 trial cohorts, with each cohort consists of 3 patients.
The estimation is updated after observing all individual out-
comes from a cohort. All experiment results are obtained
with 1000 trial repetitions. The MTD threshold is set as
θ = 0.35.
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Table 2: Recommendation & allocation percentages of different designs. Optimal biological dose is #3. In each cell the first
row reports the mean value over 1000 repetitions, and the second row reports the (standard deviation).
Recommended Allocated
Toxicity probabilities 0.01 0.05 0.15 0.2 0.45 0.6 0.01 0.05 0.15 0.2 0.45 0.6
Efficacy probabilities 0.1 0.35 0.6 0.6 0.6 0.6 0.1 0.35 0.6 0.6 0.6 0.6
SEEDA 0 1 47.20 47.40 4.40 0 11.18 9.18 30.76 31.71 12.06 5.11(0) (0.71) (3.40 ) (3.41) (2.46) (0) (0.58) (1.99) (7.76) (7.69) (3.45) (0.62)
SEEDA-Plateau 0.80 2.20 86.60 10.40 0 0 7.83 8.98 30.12 37.17 14.91 1.00(0.32) (1.96) (8.58) (3.65) (0) (0) (1.61) (4.21) (6.01) (7.54) (3.02) (0.61)
Independent TS 2.60 9.40 44.60 35.40 6.60 1.40 3.66 7.26 22.22 21.00 22.26 23.60(2.47) (3.86) (10.25) (10.32) (2.96) (0.69) (0.97) (3.85) (15.47) (10.44) (10.43) (9.22)
KL-UCB 0.20 4.60 48.80 43.60 2.80 0 10.93 7.16 21.33 20.91 21.21 18.46(0.13) (2.71) (11.68) (11.36) (2.64) (0) (0.81) (0.94) (10.52) (11.31) (10.92) (11.10)
UCB 0 2.40 54.00 40.40 3.20 0 5.45 9.50 22.13 20.93 20.43 24.57(0) (2.15) (9.92) (9.05) (3.09) (0) (0.49) (1.16) (2.11) (2.24) (2.15) (2.11)
3+3 0 2.40 12.00 17.60 45.20 22.80 16.04 17.82 20.19 18.12 16.81 5.82(0) (0.41) (4.31) (5.31) (7.15) (4.35) (5.12) (4.23) (10.25) (9.15) (8.15) (4.12)
CRM 0 0 0 33.80 65.80 0.40 0.12 0.35 2.62 33.90 57.69 5.33(0) (0) (0) (8.26) (10.63) (0.40) (0.11) (0.25) (0.32) (10.21) (11.24) (0.23)
MCRM 0 0 0.20 61.00 38.80 0 1.47 1.18 5.64 55.48 34.63 ,1.60(0) (0) (0.15) (9.67) (8.65) (0) (0.24) (0.67) (3.62) (8.63) (7.65) (0.67)
Multi-obj 0.81 3.23 47.90 41.03 5.88 1.15 18.42 21.92 23.36 18.48 9.92 7.89(0.19) (0.94) (11.86) (11.90) (1.80) (0.36) (6.07) (5.55) (6.68) (7.05) (5.17) (4.65)
The trial setup is the same as (Riviere et al., 2018) and (Zang
et al., 2014), and we have simulated eight different efficacy
and toxicity scenarios3. Due to the space limitation, we only
report the results of the first scenario, where efficacy reach-
ing the maximal value (the optimal dose) before toxicity
hits MTD threshold. Additional results for this setting as
well as the other seven scenarios are reported in Section K
to M in the supplementary material.
The following baseline designs are used for compari-
son (whenever appropriate), whose details can be found
in the supplementary material: 3+3, CRM, MCRM, In-
dependent TS, KL-UCB, UCB-1, and multi-objective
bandits. Note that MTA-RA and other TS variants in
(Riviere et al., 2018) are not included because they as-
sume a different truncated efficacy model, which needs
to be perfectly known to the algorithm. For algo-
rithms that require prior information of toxicity and effi-
cacy, they are set as [0.02, 0.06, 0.12, 0.20, 0.30, 0.40] and
[0.12, 0.20, 0.30, 0.40, 0.50, 0.59], respectively.
5.1.1. RECOMMENDATION AND ALLOCATION
ACCURACY
We report the allocation and recommendation percentages
of each dose for all considered designs in Table 2. Dose 3
(in bold font) is the optimal biological dose for this scenario.
However, we comment that dose 4 also satisfies the optimal-
ity condition without violating the safety constraint. Never-
theless, it has a higher toxicity probability (although still be-
3We remark that although no real-world trial data is utilized
in the experiment, this approach is commonly accepted in clinical
trials as the first-step study for a new methodology; see (Whitehead
et al., 2012; Yap et al., 2013; Zang et al., 2014; Riviere et al., 2018).
low MTD) without increasing efficacy; thus less preferable
to Dose 3. We note that for all the considered designs, the
recommendation rule is dˆ(n) = arg maxk:pˆk(n)≤θ qˆk(n),
where qˆk(n) and pˆk(n) are the final estimations of toxicity
and efficacy for dose level dk, respectively. This suggests
that safety constraint is considered in recommendation.
Number of Cohorts
0 50 100 150 200 250 300
Ty
pe
 I 
Er
ro
r R
at
e 
(%
)
0
2
4
6
8
10
SEEDA
SEEDA-Plateau
Indep TS
KLUCB
UCB
Multi obj
Number of Cohorts
50 100 150 200 250 300
Ty
pe
 II
 E
rr
or
 R
at
e 
(%
)
0
5
10
15
20
25
30
SEEDA
SEEDA-Plateau
Indep TS
KLUCB
UCB
Multi obj
Figure 1: Type I (left) and type II (right) error rates as a
function of number of cohorts.
We can see from the results that SEEDA almost equally
recommends dose 3 and 4 with a total probability of 94.6%.
This is because the algorithm cares about maximizing effi-
cacy without violating safety constraint, and both dose 3 and
4 satisfy such conditions. As a result, SEEDA treats both
equally as the optimal solution. However, by leveraging the
increase-then-plateau model assumption, SEEDA-Plateau
can further break the “tie” between dose 3 and 4, and cor-
rectly recognize that dose 3 is the optimal biological dose:
it chooses dose 3 at 86.6% while dose 4 only 10.4%. We
see that the gain of SEEDA-Plateau is significant over all
the other designs (even compared to SEEDA). For a more
detailed understanding of the recommendation accuracy, the
corresponding type I and type II error rates (definitions are
given in Section J in the supplementary material) are plotted
in Fig. 1, and we observe that both SEEDA and SEEDA-
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Plateau outperform other baseline methods over the range
of cohorts.
As for allocation, we observe that both SEEDA and SEEDA-
Plateau concentrate at dose 3 and 4, while spending very
little budget on both tail ends of the dosage. In particular,
SEEDA-Plateau allocates the fewest percentages (1%) of
patients to the most toxic dose 6 among all designs.
5.1.2. CONVERGENCE AND SAFETY VIOLATION
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Figure 2: Comparison of efficacy per patient (left) and the
safety violation percentage (right).
To have a deeper understanding of the tradeoff between effi-
cacy and toxicity, we plot side-by-side the convergence of
efficacy and toxicity as t increases in Fig. 2. KL-UCB, UCB
and Independent TS have good convergence but suffer from
significant safety violation in the process since they do not
consider the safety constraint during exploration. CRM has
higher efficacy at the cost of bad safety constraint violation,
while 3+3 performs poorly in efficacy but has the lowest
safety probability; this behavior is similarly observed for
multi-objective bandits. The SEEDA(-Plateau) algorithm,
in comparison, converges to the optimal efficacy at a slower
rate, but the exploration process is carefully controlled so
that the safety violation is minimized, which is evident from
the right subplot of Fig. 2.
5.1.3. SAMPLE EFFICIENCY
Sample efficiency is measured by the minimum number of
trial participants to achieve a pre-specified recommenda-
tion accuracy (also known as early stopping (Montori et al.,
2005)). We start the trial with a minimum of 6 patients,
and continue recruiting patients until the stopping condition
is triggered. Fig. 3 plots the average minimum number of
patients to achieve a given a recommendation accuracy for
different algorithms4. We see that SEEDA-Plateau outper-
forms all other algorithms by a large margin, thanks to the
“double dipping” of the model assumptions which gives the
most accurate estimation of the optimal dose. In compari-
son, SEEDA performs similarly to the baseline algorithms.
The reason is that the goal of SEEDA is to recommend the
efficacy-maximal dose that satisfies the safety constraint. In
43+3, CRM and MCRM are excluded since they only target
finding MTD.
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Figure 3: The minimum number of trial participants to
achieve a given a recommendation accuracy.
this particular setting, both dose 3 and 4 satisfy this condi-
tion, and SEEDA does not have the mechanism to further
minimize toxicity. This leads to a recommendation error
that is similar to other baseline designs.
The sample efficiency advantage of SEEDA-Plateau is of
critical importance in practice, as the significant cost associ-
ated with clinical trials is mostly proportional to the number
of trial participants. Furthermore, reducing the number of
patients while achieving the same level of accuracy mini-
mizes the safety and ethical concern in the trial, which is
another important consideration.
5.2. Real-world datasets
We evaluate the SEEDA algorithms in two real-world
datasets neurodeg and IBSCovars based on (Biesheuvel &
Hothorn, 2002). We first extract dose and resp variables
from the observations reported in the dataset. With these
samples, we fit them into a commonly used Emax dose-
response model as in (Bornkamp et al., 2011) with an R
package implementation provided by (Yoshida, 2019). The
resulting models are as follows.
neurodeg: resp = 169.94 +
12.95dose
1.85 + dose
,
IBScovars: resp = 0.26 +
0.68dose
4.01 + dose
.
As for the toxicity event, since it is not reported in the
dataset, we resort to simulations with model (1).
The allocation and recommendation percentages of each
dose for all the algorithms are shown in Table 3 and Table
4 for both datasets. We have similar observations as in
the synthetic experiment that SEEDA and SEEDA-Plateau
recommend the correct doses majority of the times, while
the suboptimal recommendation is mostly safe in that the
doses immediately below MTD are recommended second
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Table 3: Recommendation & allocation percentages of the neurodeg dataset. In each cell the first row reports the mean value
over 1000 repetitions, and the second row reports the (standard deviation).
Recommended Allocated
Toxicity 0.01 0.08 0.30 0.60 0.80 0.01 0.08 0.30 0.60 0.80
Efficacy 0.01 0.35 0.45 0.52 0.57 0.01 0.35 0.45 0.52 0.57
SEEDA 0.60 32.91 66.14 0 0 5.58 34.14 59.60 0.33 0.33(0.40) (10.57) (10.59) (0) (0) (0.42) (6.08) (6.25) (0.25) (0.01)
SEEDA-Plateau 0.99 32.66 66.00 0 0 5.09 35.02 59.21 0.33 0.33(0.31) (10.12) (10.36) (0) (0) (2.05) (7.78) (6.64) (0.02) (0)
Independent TS 3.39 51.28 44.47 0.38 0.46 0.80 3.50 7.59 23.37 64.68(2.56) (9.92) (10.34) (0.33) (0.37) (0.60) (2.70) (5.21) (10.19) (12.51)
KL-UCB 0.07 55.74 28.67 5.43 0.07 98.0 0.42 0.47 0.52 0.55(0.06) (12.38) (12.76) (2.10) (0.05) (2.62) (0.23) (0.28) (0.49) (0.04)
UCB 0.81 41.68 57.24 0.23 0.01 6.88 15.09 20.10 25.75 32.16(0.74) (16.07) (16.07) (0.17) (0.01) (0.29) (1.60) (2.10) (2.55) (2.87)
3+3 0 2.40 12.00 17.60 45.20 16.04 17.82 20.19 18.12 16.81(0) (1.02) (2.35) (3.44) (10.34) (5.60) (9.48) (1.84) (1.60) (4.20)
CRM 0 0 0 100 0 0 0 0 99.66 0.33(0) (0) (0) (0) (0) (0) (0) (0) (0.01) (0.01)
MCRM 4.33 26.47 69.18 0 0 4.67 26.40 68.92 0 0(0.25) (1.80) (1.86) (0) (0) (0.25) (1.80) (2.10) (0) (0)
Multi-obj 0.24 15.33 17.59 0.12 0.03 24.33 26.12 18.95 16.05 14.52(0.13) (9.65) (9.71) (0.05) (0.03) (4.28) (3.51) (6.11) (2.93) (2.61)
most. The same is true for allocation.
6. Related works
This work is concerned with adaptive phase I clinical trials,
whose uptake in practice is starting to increase considerably.
See (Bretz et al., 2017; Pallmann et al., 2018) for recent
comprehensive surveys. The main motivation to use these
adaptive designs is to learn as the trial progresses and use
this learning to deliver more efficient or more ethically ap-
pealing trials. Adaptive clinical trial with sequential patient
recruitment is considered in (Atan et al., 2019), but it does
not address the subsequent dose allocation. The 3+3 and the
CRM designs or their variations remain the de facto adaptive
designs in practice for dose-finding studies (Petroni et al.,
2017; Pallmann et al., 2018), although new methodologies
that aim at better safety protection are also proposed (Lee
et al., 2017). In recent years, there is a growing interest
in adaptive trial designs for MTA because of its different
dose-response relationships (Zang et al., 2014; Riviere et al.,
2018), but these studies do not explicitly enforce the safety
constraints during the trial; neither do they provide theoreti-
cal guarantees on the trial performance.
Multi-armed bandit has long been considered as an impor-
tant tool for learning in clinical trials, dating back to the
earliest papers of (Thompson, 1933; Robbins, 1952). De-
veloping bandit models and algorithms that better suit the
specific requirements of adaptive clinical trials has attracted
some attention in recent years. Villar et. al (Villar et al.,
2015b; Villar & Rosenberger, 2018) adopted the (modified)
forward-looking Gittins index rule for multi-arm clinical
trials. The authors of (Wang et al., 2018) propose a regional
bandit model that can be applied to learning the drug dosage
and patient response relationship. The sample complexity
of thresholding bandit is analyzed in (Garivier et al., 2017),
which matches MTD identification. Probably the closest
work to ours is (Aziz et al., 2019), which also considers
both toxicity and efficacy. However, the safety constraint,
which is an essential constraint of real-world phase I trials,
has not been explicitly considered in these papers.
7. Conclusions
Learning in adaptive clinical trials faces several unique chal-
lenges that have not been well addressed, which may have
contributed to their lack of adoption in actual clinical trials.
In particular, the safety constraints resulting from ethical and
societal considerations have been insufficiently researched,
which has motivated us to develop the SEEDA algorithm
that explicitly imposes safety constraints (in terms of tox-
icity) while also aiming for maximum patient response in
a dose-finding study. Theoretical analysis of SEEDA is
carried out and the proposed algorithm is further extended
to the increase-then-plateau efficacy model and shown to
have smaller regret thanks to the unimodal structure. The
performance advantages over state-of-the-art adaptive clin-
ical trial designs are illustrated with experiments on both
synthetic and real-world datasets.
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Table 4: Recommendation & allocation percentages of the IBScovars datasets. In each cell the first row reports the mean
value over 1000 repetitions, and the second row reports the (standard deviation).
Recommended Allocated
Toxicity probabilities 0.01 0.10 0.30 0.70 0.95 0.01 0.10 0.30 0.70 0.95
Efficacy probabilities 0.01 0.20 0.27 0.33 0.43 0.01 0.20 0.27 0.33 0.43
SEEDA 1.14 35.04 63.47 0 0 10.11 34.35 54.86 0.33 0.33(1.31) (7.58) (7.60) (0) (0) (0.82) (5.42) (5.57) (0.17) (0.01)
SEEDA-Plateau 2.08 36.51 61.06 0 0 8.97 34.60 55.75 0.33 0.33(2.76) (10.31) (10.42) (0) (0) (4.00) (4.34) (7.83) (0.02) (0.01)
Independent TS 7.52 48.47 43.30 0.31 0.39 1.82 3.89 26.66 20.65 23.17(7.15) (9.79) (9.71) (0.60) (0.17) (0.85) (3.61) (10.74) (13.54) (10.05)
KL-UCB 28.55 44.90 23.24 3.28 0 98.33 0.37 0.40 0.42 0.45(9.21) (9.95) (10.06) (2.60) (0) (0.35) (0.44) (0.87) (0.06) (0.60)
UCB 1.73 45.26 52.81 0.17 0.01 9.41 15.37 18.94 23.22 33.04(1.21) (9.21) (9.25) (0.08) (0.01) (0.38) (1.45) (1.87) (2.26) (2.61)
3+3 2.40 12.00 17.60 45.20 22.80 16.04 17.82 20.19 18.12 22.81(0.88) (7.65) (6.87) (6.86) (8.87) (2.85) (5.29) (8.29) (5.52) (5.45)
CRM 0 0 0 1.35 98.65 0 0 0 99.66 0.33(0) (0) (0 ) (0.10) (0.04) (0) (0) (0) (0.86) (0.03)
MCRM 4.34 26.91 68.74 0 0 4.67 26.83 68.49 0 0(0.26) (2.15) (2.20) (0) (0) (0.04) (0.05) (0.91) (0) (0)
Multi-obj 0.45 16.18 16.56 0.10 0.02 1.23 3.27 5.79 13.11 76.56(0.25) (5.49) (10.53) (0.03) (0) (1.14) (3.12) (5.12) (6.43) (6.04)
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A. Preliminaries
Before presenting the technical proofs, we introduce some notations and regularity assumptions on the dose-toxicity model, which can be
verified for Eqn. (1). For a general toxicity function pk(a) of an unknown parameter a ∈ A, the following regularities are imposed:
Assumption 2 1) Monotonicity: For each k ∈ K and a, a′ ∈ A there exists C1,k > 0 and 1 < γ1,k, such that |pk(a)− pk(a′)| ≥
C1,k|a− a′|γ1,k .
2) Hölder continuity: For each k ∈ K and a, a′ ∈ A there exists C2,k > 0 and 0 < γ2,k ≤ 1, such that |pk(a) − pk(a′)| ≤
C2,k|a− a′|γ2,k .
We note that both monotonicity and continuity assumptions are mild and standard in the literature; see (Wang et al., 2018). Proposition 1
immediately follows with Assumption 2.
Proposition 1 For functions pk(a), ∀k ∈ K that satisfy Assumption 2, we have:
1) pk(a) is invertible;
2) For each k ∈ K and d, d′ ∈ P , there exists |p−1k (d)− p−1k (d′)| ≤ C¯1,k|d− d′|γ¯1,k , where γ¯1,k = 1γ1,k , C¯1,k = (
1
C1,k
)
1
γ1,k .
For ease of exposition, we denote C1 = minC1,k, C2 = maxC2,k, γ1 = max γ1,k, γ2 = min γ2,k, γ¯1 = 1/γ1, and C¯1 = C−γ¯11 .
B. Select Design Parameters
The parameters appeared in Assumption 2 collectively determine the confidence interval in Eqn. (3). In practice, if the function pk(a) is
known, we could select the parameters either theoretically or experimentally. Taking function (1) as an example, we have
|pk(a)− pk(a′)| ≥ C1,k|a− a′|γ1,k ,
|pk(a)− pk(a′)|
|a− a′| ≥ C1,k|a− a
′|γ1,k−1,
min
a∈A
p′k(a) ≥ C1,k|A|γ1,k−1,
log
(
tanh(dk) + 1
2
)
≥ C1,k|A|γ1,k−1.
Therefore, we can first set γ1,k as 32 and find the corresponding C1,k. Then, with the known function, parameters can be approximately
calculated.
C. Proof of Lemma 1
P[aˆ(t) + α(t) < p−1i (θ)] ≤ P[aˆ(t) + α(t) < a∗]
≤ P[|a∗ − aˆ(t)| > α(t)]
≤ P
[
K∑
k=1
wk(t− 1)C¯1|pˆk(t)− pk(a∗)|γ¯1 > α(t)
]
≤
K∑
k=1
P
[
|pˆk(t)− pk(a∗)| >
(
α(t)
wk(t− 1)C¯1K
)γ1]
≤
K∑
k=1
2 exp
(
−2Nk(t)
(
α(t)
wk(t)C¯1K
)2γ1)
(11)
≤ 2K exp
(
−2
(
α(t)
C¯1K
)2γ1
t
)
= δ. (12)
Inequality (11) is from the Hoeffding’s inequality and (12) is derived from the definition of Nk(t) = twk(t) and Assumption 2 with
γ1 > 1.
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D. Proof of Lemma 2
From the Hoeffding’s Inequality and Eqn. (6), we have:
α(t) ≤ p−1k (θ)− a∗ −  = ∆k − ,
where ∆k = |a∗ − p−1k (θ)| denotes the gap between the true value of parameter a and the parameter corresponding to when the toxicity
of dose level dk is exactly at the MTD threshold θ. When t > t1 and with the definition of α(t) in Eqn. (3), the lemma can be immediately
derived.
E. Proof of Theorem 1
Depending on whether the optimal dose level is included in the admissible set or not, we can decompose the regret into two parts:
R(n) =
n∑
t=1
P[k∗ /∈ D1(t)]Q+ P[k∗ ∈ D1(t)]R2(n)
≤ TδQ+R2(n).
The probability of the first error event {k∗ /∈ D1(t)} can be bounded by Lemma 1, which indicates that at each step t the probability of a
safe dose level being excluded from the admissible set is bounded by δ. For the second part, R2(n) represents the regret when the optimal
dose is included in the admissible set. In this case, the error event is due to the inaccuracy of parameter estimation at the beginning as well
as the limited efficacy information provided by each sample. Using Lemma 2, we have:
R2(n) ≤ t1 + (K −M)
n∑
t=1
exp(−2t2) +
n∑
t=t1+1
∑
dk:pk≤θ
1{I(t) = k}
≤ t1 + K −M
22
+
∑
dk:pk≤θ
c log(n)
q∗ − qk .
Putting the regret from both error events together leads to (7), which completes the proof.
F. Proof of Theorem 2
First we note:
pI(t)(a
∗)− θ ≤ pI(t)(a∗)− θ + θ − pI(t)(a∗ − α(t))
≤ C2|a∗ − aˆ(t) + α(t)|γ2 .
Thus, the probability can be upper bounded as:
P[aˆ(t)− a∗ > α(t) + ] ≤ exp(−2t(α(t) + )2).
Reorganizing the terms, we finally have
P
[
1
n
n∑
t=1
pI(t)(a
∗)− θ < C2γ2
]
≥ 1− exp(−2t(α(t) + )2) ≥ 1− δ.
G. Proof of Corollary 2
P[|aˆ(n)− a∗| ≥ ∆M ] ≤
K∑
k=1
P
[
|pˆk(t)− pk(a∗)| >
(
∆M
wk(t)C¯1K
)γ1]
≤
K∑
k=1
2 exp
(
−2Nk(n)
(
∆M
wk(t)C¯1K
)2γ1)
≤ 2K exp
(
−2
(
∆M
C¯1K
)2γ1
n
)
.
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H. Proof of Theorem 3
We first establish Lemma 3, whose proof directly follow Theorem C.1 in (Combes & Proutière, 2014).
Lemma 3 E[lk(n)] = O(log(log(n))), for each k 6= k∗.
Then, following the similar proof steps in Theorem 1, we have the bound in (9).
I. Proof of Theorem 4
Since φ∗ = min{M,N} and L1(n) and L2(n) are the estimations for N and M respectively, {dˆr(n) 6= φ∗} ⊆ E1⋃E2, where
E1 = {L1(n) 6= N}, E2 = {L2(n) 6= M}. The latter can be bounded by Corollary 2. With the notation βk(n) =
√
c log(n)
Nk(n)
, the
probability of E1 can be bounded as follows:
P[L1(n) < M ] ≤ P[|qˆN (n)− qˆN−1(n)| ≤ βN−1(n) + βN (n)]
≤ P[qˆN−1(n)− qk + qN − qˆN (n) ≤ qN − qN−1 − βN−1(n)− βN (n)]
≤ 2 exp
(
−2NN−1(n)
(
qN − qN−1 − βN−1(n)− βN (n)
2
)2)
≤ 2 exp
(
−2f(N − 1) log(n)
(
∆N−1,N − βN−1(n)− βN (n)
2
)2)
= o
(
n−
5
2
)
.
Furthermore,
P[L1(n) > M ] ≤ P[|qˆN (n)− qˆN+1(n)| > βN (n) + βN+1(n)]
≤ P[|qˆN (n)− qN |+ |qN+1 − qˆN+1(n)| > βN (n) + βN+1(n)]
≤ P[|qˆN (n)− qN | > βN (n)] + P[|qˆN+1(n)− qN+1| > βN+1(n)]
≤ 2
nc
.
Lastly, f(N − 1) is the coefficient of the lower bound of NN−1(n), and can be written as (see Theorem 4.1 in (Combes & Proutière,
2014))
f(N − 1) = 1
I(qN−1, qN )
.
This completes the proof.
J. Baseline designs in the experiments
The following baseline designs are used for comparison to SEEDA and SEEDA-Plateau in the experiments.
• KL-UCB (Garivier & Cappè, 2011): This approach ignores the safety constraint and focuses entirely on efficacy during allocation,
as for each patient it allocates the dose level with the highest efficacy index. The efficacy performance for each dose level
is characterized by the KL-UCB index. However, at the end of the experiment, a dose level is recommended according to
dˆ(n) = arg maxk:pˆk(n)≤θ qˆk(n), where qˆk(n) and pˆk(n) are the last empirical estimations of toxicity and efficacy for dose level
dk. This suggests that safety constraint is considered in recommendation. Accordingly, type I and type II errors are defined as:
e1 =
∑
k∈K
1{pk ≤ θ}1{pˆk(n) > θ},
e2 =
∑
k∈K
1{pk > θ}1{pˆk(n) ≤ θ}.
• UCB-1 (Auer et al., 2002): The allocation and recommendation rules are similar to KL-UCB above, with the only difference that
the dose level with the highest UCB-1 index of efficacy is allocated to the patient.
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• Independent Thompson Sampling (TS) (Thompson, 1933; Aziz et al., 2019): Toxicity and efficacy are estimated with Bayesian
indices:
p˜k(t) ∼ Beta(Spk(t) + 1, Nk(t)− Spk(t) + 1),
and
q˜k(t) ∼ Beta(Sqk(t) + 1, Nk(t)− Sqk(t) + 1),
where Spk(t) counts the number of toxic outcomes of dose level k among the first t patients and S
q
k(t) counts the number of effective
responses. The dose with maximum q˜k(t) is allocated to the t-th patient and dˆ(n) = arg maxk:p˜k(n)≤θ q˜k(n) is recommended.
Definitions of type I and type II errors are slightly modified to:
e1 =
∑
k∈K
1{pk ≤ θ}1{p˜k(n) > θ},
e2 =
∑
k∈K
1{pk > θ}1{p˜k(n) ≤ θ}.
• CRM (O’Quigley et al., 1990): We here employ the CRM algorithm with the same one-parameter toxicity model in our paper:
pk(a) =
(
tanh(dk) + 1
2
)a
.
We choose a typical prior distribution as a ∼ exp(0.5). Therefore, dk can be solved with priortox and the prior mean of a. pit(a)
denotes the posterior distribution of a after observing the outcomes of the first t patients. The allocation rule is a greedy one:
ICRMt = arg min
k∈K
|θ − pk(aˆ(t))|,
aˆ(t) =
∫ ∞
0
adpit(a),
where aˆ(t) is the posterior mean value. With this estimation, the final recommendation rule can be written as:
dˆ(n) = arg min
k∈K
|θ − pk(aˆ(n))|.
• 3+3 (Storer, 1989): The lowest dose is first given to 3 patients. If none reports a toxic outcome, the next lowest dose level is given to
the next 3 patients. If there are less than 2 among these 6 patients who report toxic outcome, the next lowest dose level is given to
the next 3 patients; otherwise the experiment is stopped and the dose level used before stopping is recommended as MTD.
• MCRM (Neuenschwander et al., 2008): This algorithm classifies the probability of toxicity into four categories. For our simulated
setting, the categories are set as:
Under-dosing: pia(d) ∈ (0, 0.20]
Targeted toxicity: pia(d) ∈ (0.20, 0.35]
Excessive toxicity: pia(d) ∈ (0.35, 0.60]
Unacceptable toxicity: pia(d) ∈ (0.60, 1.00]
The recommendation and the allocation rules are to maximize the probability of targeted toxicity while controlling the probability
of excessive or unacceptable toxicity at P thre = 25%. Based on the posterior distribution of the toxicity, the probability that the
toxicity falls in the above four categories can be calculated. The probability that it falls in Targeted category is denoted as P ti while
falls in Excessive and Unacceptable categories as P ei . The selection rule is therefore It = arg max
Pei ≤P thre
P ti .
• Multi-objective Bandits (Yahyaa & Manderick, 2015): We implement the Pareto Thompson Sampling algorithm of (Yahyaa &
Manderick, 2015) in our experiments. Specifically, after getting the estimations of toxicity and efficacy of each dose from running the
Independent TS design, the algorithm computes the Pareto optimal dose level set I∗, which means ∀i ∈ I∗, ∀j /∈ I∗, p˜i(t) ≤ p˜j(t)
or q˜i(t) ≥ q˜j(t).
Other policies designed for MTA, such as MTA-RA, depend on a different truncated two-parameter logistic efficacy model (Riviere et al.,
2018). In our setting, the exact efficacy model is assumed to be unknown – we only make the increase-then-plateau assumption.
K. Additional experiment results under the same setting as in Section 5
Due to space limitations, we were not able to include all the experiment results of the setting in Section 5. These additional results are
provided here.
In particular, Table 2 only reports the recommendation and allocation percentages for a given n = 100. It is of interest to see how these
metrics change with n. We plot the mean allocation and recommendation probabilities as a function of n in Fig. 4. It can be seen that
SEEDA-Plateau outperforms all other methods across a large range of n.
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Figure 4: Mean allocation (left) and recommendation (right) probabilities versus number of patients n.
L. Experiment of a new setting and its comprehensive results
In the main paper, a setting that has the efficacy reaching the maximal value (the optimal dose) before toxicity hits MTD threshold is used.
A different setting exists when maximum efficacy dose exceeds the MTD threshold. The experiment results for this setting (called “setting
2”) is reported here. Unless otherwise stated, the parameters are the same as in Section 5 of the main paper.
Table 5 presents the setting as well as the allocation and recommendation percentages of each dose for all considered algorithms. For this
scenario, dose level 3 is the optimal one. We note that a large portion of the previous conclusions in the main paper still hold. However,
the gain of SEEDA-Plateau is less significant over SEEDA, but still outperforms all the comparing designs. The corresponding Type I and
Type II error rates are similarly plotted in Fig. 6.
Table 5: Recommendation & allocation percentages of different designs for setting 2.
Recommended Allocated
Toxicity probabilities 0.1 0.2 0.25 0.4 0.5 0.6 0.1 0.2 0.25 0.4 0.5 0.6
Efficacy probabilities 0.3 0.4 0.5 0.7 0.7 0.7 0.3 0.4 0.5 0.7 0.7 0.7
SEEDA 9.54 19.34 52.66 16.00 2.12 0 6.82 17.61 48.99 21.77 3.47 1.33(3.40) (10.09) (10.43) (9.95) (1.70) (0) (3.34) (5.56) (9.60) (1.07) (1.32) (0.61)
SEEDA-Plateau 5.15 34.51 53.27 5.84 1.05 0.01 3.61 11.79 70.30 11.97 2.16 0.17(3.72) (5.96) (6.80) (2.64) (0.50) (0) (2.28) (1.79) (7.51) (5.12) (0.42) (0.12)
Independent TS 22.61 22.12 29.05 19.22 4.50 2.50 2.58 3.17 5.56 30.35 32.92 25.43(5.61) (7.43) (8.24) (5.96) (2.41) (2.01) (1.90) (2.23 ) (3.72) (4.73) (4.62) (3.82)
KL-UCB 19.72 21.03 29.19 24.02 5.46 0.59 2.13 2.50 3.37 32.80 30.63 28.58(3.65) (4.14) (9.27) (5.44) (1.88) (0.38) (0.48 ) (0.78) (1.35) (3.77 ) (8.16) (6.99)
UCB 8.95 22.45 41.04 21.61 4.83 1.11 8.12 10.31 13.20 22.90 22.58 22.89(3.77) (7.99) (8.20) (3.65) (4.56) (1.18) (0.88) (1.13) (1.47) (2.13) (1.75) (2.89)
3+3 6.80 20 23.80 29.80 16.40 3.20 26.99 27.50 19.59 13.14 5.01 0.76(0.12) (13.40) (10.24) (8.45) (5.45) (3.12) (2.89) (3.25) (1.45) (0.25) (1.25) (0.75)
CRM 0 0 0 0 99.10 0.90 0 0 0 0 99.11 0.89(0) (0) (0) (0) (0.42) (0.36) (0) (0) (0) (0) (0.23) (0.14)
MCRM 0 0.60 28.40 67.80 3.20 0 0.60 0.33 29.17 52.37 11.35 3.18(0) (0.93) (13.29) (13.95) (3.06) (0) (0.09) (0.12) (9.47) (13.95) (4.34) (1.92)
Multi-obj 6.57 13.38 50.95 22.71 4.44 1.95 20.17 14.78 19.05 20.29 14.57 11.17(2.64) (8.12) (9.92) (6.95) (1.27) (0.55) (5.32) (2.02) (3.95) (3.25) (5.56) (3.58)
An in-depth look at the mean allocation and recommendation probabilities versus number of patients n for this new setting is given in
Fig. 5. The same observation as in Section K holds.
The convergence of efficacy and toxicity as t increases for setting 2 is plotted in Fig. 7. There is a notable difference to the previous result
in Fig. 2, in that now SEEDA and SEEDA-Plateau converge to a different (but correct) dose than the other considered designs, which only
emphasize maximum efficacy. It is clear that with such aggressive pursue of efficacy, they succeed in obtaining better treatment effect
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Figure 5: Mean allocation (left) and recommendation (right) probabilities versus number of patients n in setting 2.
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Figure 6: Type I and type II error rates in setting 2.
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Figure 7: Comparison of efficacy per patient and the safety violation percentage in setting 2.
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Figure 8: Sample size comparison in setting 2.
than SEEDA(-Plateau), but at the significant cost of frequent violation of the safety constraint: as opposed to safety violation percentage
hovering between 40% and 50% in Fig. 2, now we face a violation in the range of 70% to 90% as shown in Fig. 7.
Lastly, the sample efficiency is evaluated. Fig. 8 plots the minimum number of patients to achieve a given a recommendation accuracy for
different algorithms.
M. Experiment setting 3 to 8 with evaluation of allocation and recommendation percentages
This section reports the allocation and recommendation percentages of each dose for all considered algorithms under different toxic-
ity/efficacy probabilities. We reuse the same 6 scenarios as those in the experiments of (Zang et al., 2014). See Table 6 to 11 for the
detailed results. They are in line with the conclusions of the main paper.
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Table 6: Recommended & allocated percentages for Scenario 1 of (Zang et al., 2014).
Recommended Allocated
Toxicity probability 0.08 0.12 0.2 0.3 0.4 0.08 0.12 0.2 0.3 0.4
Efficacy probability 0.2 0.4 0.6 0.8 0.55 0.2 0.4 0.6 0.8 0.55
SEEDA 2.72 4.88 21.72 69.52 1.16 2.84 4.67 18.55 71.20 2.74(1.01) (2.14) (7.50) (10.11) (0.62) (0.78) (1.95) (6.04) (7.65) (2.74)
Indep TS 2.34 4.38 12.91 76.83 3.54 1.67 2.99 7.93 81.18 6.23(0.25) (1.31) (6.34) (7.03) (1.49) (0.62) (0.64) (0.36) (2.55) (2.44)
KL-UCB 9.58 23.99 39.35 24.27 2.81 3.24 13.89 30.91 22.35 29.61(1.57) (3.53) (8.10) (9.13) (2.28) (0.34) (0.51) (1.64) (2.14) (1.12)
UCB 3.04 12.41 46.91 35.24 2.40 10.91 18.41 33.34 28.32 9.02(0.91) (3.11) (8.68) (7.68) (1.99) (0.72) (1.31) (2.10) (2.67) (1.85)
3+3 4 10.40 20 22.80 42.80 23.38 22.81 20.92 15.80 10.79(2.65) (4.73) (5.94) (2.73) (6.95) (5.79) (1.22) (4.63) (2.14) (1.26)
CRM 0.09 0.20 1.72 42.51 55.48 0.09 0.20 1.72 42.51 55.48(0.02) (0.02) (0.02) (2.38) (2.38) (0.02) (0.02) (0.02) (2.38) (2.38)
MCRM 1.09 2.26 26.69 65.68 4.28 2.09 2.26 26.50 64.88 4.28(1.01) (2.20) (7.69) (9.26) (2.10) (1.31) (2.20) (6.68) (8.25) (0.13)
Multi-obj 1.41 4.56 22.69 67.31 4.03 18.42 20.69 22.51 31.41 6.97(1.13) (3.97) (8.44) (9.93) (3.29) (1.31) (2.40) (6.67) (8.25) (1.23)
Table 7: Recommended & allocated percentages for Scenario 2 of (Zang et al., 2014).
Recommended Allocated
Toxicity probability 0.01 0.05 0.10 0.15 0.3 0.01 0.05 0.10 0.15 0.3
Efficacy probability 0.6 0.8 0.5 0.4 0.2 0.6 0.8 0.5 0.4 0.2
SEEDA 6.3 91.23 1.45 0.53 0.08 5.56 87.26 2.95 2.14 2.09(0.90) (3.18) (1.02) (0.34) (0.08) (3.11) (3.94) (2.09) (1.43) (0.63)
Indep TS 5.31 92.09 1.47 0.64 0.48 7.99 83.18 4.27 2.91 1.65(4.95) (1.32) (1.08) (0.56) (0.16) (2.55) (5.34) (4.34) (2.30) (1.05)
KL-UCB 9.68 87.66 1.91 0.66 0.09 7.01 81.93 3.03 2.31 5.72(2.73) (2.98) (1.20) (0.44) (0.04) (1.57) (1.94) (0.82) (0.51) (0.31)
UCB 8.58 89.80 1.26 0.34 0.03 21.06 46.31 15.07 11.16 6.40(3.98) (4.18) (1.24) (0.24) (0.03) (2.20) (2.69) (1.68) (1.28) (0.73)
3+3 0.20 1.80 5.40 13.80 78.80 16.71 18.81 19.40 19.88 19.75(0) (0.32) (0.78) (2.37) (8.34) (3.35) (3.65) (3.78) (3.14) (4.65)
CRM 0 0 0 9.98 90.02 0 0 0 9.97 90.03(0) (0) (0) (0.42) (0.42) (0) (0) (0) (1.25) (1.43)
MCRM 0.08 0.17 1.15 13.47 85.13 1.08 0.17 1.15 13.44 84.16(0) (0.02) (1.00) (0.44) (0.04) (0.27) (0.09) (0.61) (5.76) (6.73)
Multi-obj 6.07 90.85 1.93 0.92 0.22 34.88 51.74 7.11 4.34 1.93(1.74) (1.86) (0.54) (0.30) (0.11) (7.26) (6.81) (2.41) (1.20) (0.50)
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Table 8: Recommended & allocated percentages for Scenario 3 of (Zang et al., 2014).
Recommended Allocated
Toxicity probability 0.06 0.08 0.14 0.2 0.3 0.06 0.08 0.14 0.2 0.3
Efficacy probability 0.2 0.4 0.6 0.8 0.55 0.2 0.4 0.6 0.8 0.55
SEEDA 1.84 1.97 6.15 88.12 1.58 2.27 2.54 6.27 85.46 3.46(0.71) (1.10) (2.86) (3.22) (1.00) (0.71) (1.11) (2.86) (3.22) (0.99)
Indep TS 0.76 1.55 5.49 89.85 2.35 1.67 2.98 8.17 81.28 5.89(0.45) (0.93) (3.71) (5.09) (1.73) (0.48) (1.33) (4.48) (4.96) (1.79)
KL-UCB 2.64 7.29 28.47 57.18 4.43 2.62 6.58 26.85 55.07 8.87(0.54) (1.15) (3.22) (3.58) (1.41) (0.54) (1.15) (3.22) (3.58) (1.41)
UCB 1.71 3.57 19.04 72.89 2.79 8.33 13.17 22.75 44.71 11.04(0.48) (1.33) (4.48) (4.96) (1.79) (0.48) (1.33) (4.48) (4.96) (1.79)
3+3 2.20 4.80 10.60 18.80 63.60 19.77 20.08 20.43 18.67 15.29(1.93) (2.10) (3.22) (3.92) (9.33) (3.54) (5.93) (5.12) (3.95) (3.45)
CRM 0 0 0 4.37 95.63 0 0 0 4.37 95.63(0) (0) (0) (0.69) (0.69) (0) (0) (0) (0.66) (0.66)
MCRM 0.60 0.87 3.57 31.89 63.07 1.60 0.87 3.57 31.68 62.28(0.54) (0.15) (3.22) (3.58) (1.41) (0.98) (1.26) (2.97) (8.86) (10.58)
Multi-obj 0.78 2.07 8.67 84.99 3.49 16.43 20.56 21.56 34.45 7.00(0.20) (0.45) (1.97) (2.40) (1.02) (0.20) (0.45) (1.97) (2.41) (1.02)
Table 9: Recommended & allocated percentages for Scenario 4 of (Zang et al., 2014).
Recommended Allocated
Toxicity probability 0.05 0.1 0.25 0.5 0.6 0.05 0.1 0.25 0.5 0.6
Efficacy probability 0.2 0.4 0.6 0.8 0.55 0.2 0.4 0.6 0.8 0.55
SEEDA 3.43 12.15 79.72 4.37 0 3.40 11.05 79.44 5.00 1.12(1.26) (3.69) (4.25) (1.90) (0) (1.24) (3.48) (4.28) (1.75) (0.45)
Indep TS 11.53 24.58 58.58 2.66 2.65 1.68 3.02 8.50 81.01 5.79(9.17) (10.80) (12.42) (1.53) (3.42) (0.99) (2.39) (5.40) (16.00) (6.50)
KL-UCB 24.60 37.78 28.34 6.91 2.37 1.91 2.43 3.41 51.61 40.64(6.65) (14.78) (14.62) (2.00) (2.78) (0.32) (0.52) (1.41) (1.89) (1.06)
UCB 4.87 32.53 60.34 1.84 0.42 14.29 26.93 40.69 9.15 8.94(5.17) (10.80) (14.42) (1.52) (0.42) (0.72) (1.31) (2.11) (2.63) (1.85)
3+3 3 6.20 34.20 40.40 16.20 22.57 22.82 26.70 17.10 4.29(1.46) (4.64) (6.85) (7.10) (4.16) (7.69) (6.98) (7.89) (6.79) (0.68)
CRM 0 0 0 95.56 4.44 0 0 0 95.23 4.77(0) (0) (0) (0.14) (0.14) (0) (0) (0) (2.12) (2.12)
MCRM 0.84 3.77 88.03 7.17 0.19 1.84 3.77 87.04 7.16 0.19(0.83) (1.73) (3.92) (3.58) (0.01) (0.83) (1.73) (3.91) (3.57) (0.01)
Multi-obj 3.64 19.66 70.79 4.80 1.11 19.93 23.96 23.97 26.16 5.98(0.66) (4.87) (5.13) (1.18) (0.41) (6.11) (4.93) (4.69) (4.17) (2.25)
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Table 10: Recommended & allocated percentages for Scenario 5 of (Zang et al., 2014).
Recommended Allocated
Toxicity probability 0.1 0.2 0.4 0.5 0.6 0.1 0.2 0.4 0.5 0.6
Efficacy probability 0.1 0.3 0.5 0.5 0.5 0.1 0.3 0.5 0.5 0.5
SEEDA 7.20 74.95 15.01 2.50 0 6.86 67.46 21.21 3.22 1.26(1.10) (4.42) (4.84) (1.46) (0) (0.96) (3.49) (4.11) (1.58) (0.61)
SEEDA-Plateau 12.60 82.20 4.60 0.60 0 19.50 56.46 15.49 7.56 1.00(2.12) (5.45) (2.12) (0.40) (0) (5.12) (9.23) (4.56) (1.23) (0.54)
Indep TS 21.59 50.75 21.15 4.73 1.78 2.67 6.34 29.19 30.59 31.22(7.05) (10.00) (11.41) (1.91) (1.42) (1.52) (6.28) (6.32) (6.41) (6.14)
KL-UCB 23.64 40.01 21.58 10.92 3.85 3.80 2.24 23.69 40.19 30.10(4.52) (10.18) (10.82) (2.16 ) (0.81) (0.75) (1.38) (10.60) (9.94) (10.93)
UCB 13.71 75.24 8.66 1.85 0.54 18.75 36.38 16.49 14.23 14.14(1.63 ) (9.14) (5.79) (0.79) (0.96) (0.64) (4.19) (2.57) (2.63) (2.55)
3+3 7.40 21.20 42.60 21.80 7.00 29.03 29.38 23.97 8.35 1.76(1.42) (12.30) (6.42) (3.06) (4.12) (0.79) (3.32) (2.14) (1.15) (0.42)
CRM 0 0 0 94.72 5.28 0 0 0 94.39 5.61(0) (0) (0) (0.04) (0.05) (0) (0) (0) (0.02) (0.02)
MCRM 2.86 62.72 33.03 1.25 0.14 3.86 62.02 32.73 1.25 0.14(0.80) (1.66) (4.13) (4.05) (0) (0.80) (1.66) (4.11) (0.42) (0.02)
Multi-obj 9.56 60.18 23.51 5.38 1.38 23.42 25.22 22.55 16.27 12.54(0.58) (3.92) (4.17) (1.00) (0.39) (6.89) (5.30) (5.28) (6.61) (5.79)
Table 11: Recommended & allocated percentages for Scenario 6 of (Zang et al., 2014).
Recommended Allocated
Toxicity probability 0.01 0.03 0.05 0.1 0.2 0.01 0.03 0.05 0.1 0.2
Efficacy probability 0.1 0.3 0.45 0.6 0.6 0.1 0.3 0.45 0.6 0.6
SEEDA 1.47 1.79 5.12 48.97 42.32 3.59 2.93 5.89 45.65 41.94(0.45) (1.16) (3.94) (10.31) (12.35) (0.56) (1.55) (3.19) (6.51) (6.62)
SEEDA-Plateau 0 0.20 3 96 0.80 4.20 5.64 13.73 40.22 36.18(0) (0.05) (1.38) (5.72) (0.56) (3.75) (2.45) (5.42) (9.85) (4.75)
Indep TS 0.42 1.24 5.20 47.46 45.67 13.71 18.37 22.33 28.10 17.48(0.31) (0.86) (3.13) (12.35) (12.22) (1.06) (3.55) (5.87) (8.80) (8.57)
KL-UCB 1.96 2.55 9.57 54.30 31.62 3.78 3.32 9.42 52.03 31.45(0.50) (1.46) (3.46) (10.30) (10.06) (0.77) (0.76) (2.14) (10.56) (10.53)
UCB 1.31 2.06 9.47 56.47 30.69 8.18 12.58 19.54 32.85 26.84(0.37) (1.22) (4.06) (10.82) (10.74) (0.58) (1.30) (2.02) (2.83) (2.93)
3+3 0 1.40 2.20 8.20 88.20 17.14 18.15 18.32 20.07 20.74(0) (0.23) (1.23) (1.27) (7.21) (6.79) (7.90) (7.45) (6.52) (6.48)
CRM 0 0 0 65.39 34.61 0 0 0 65.15 34.85(0) (0) (0) (2.29) (2.29) (0) (0) (0) (6.79) (6.41)
MCRM 0.06 0.08 0.49 2.92 96.45 1.06 0.08 0.48 2.92 95.45(0.02) (0.04) (0.50) (1.21) (3.00) (0.25) (0.04) (0.29) (2.01) (3.00)
Multi-obj 0.63 1.60 6.78 49.01 41.98 13.71 18.37 22.33 28.10 17.48(0.17) (0.36) (1.52) (10.01) (10.03) (7.55) (8.18) (8.00) (7.23) (7.41)
